An independent Centers for Disease Control and Prevention advisory committee today recommended immediate resumption of the administration of Johnson & Johnson’s COVID-19 vaccine in the U.S. The vaccine maker would add a warning to its labeling materials about the risk of rare blood clots known as thrombosis with thrombocytopenia syndrome. The recommendation, which passed by a 10-4 vote with one abstention, now goes to the CDC for its approval. The Food and Drug Administration will amend Johnson & Johnson’s emergency use authorization to indicate that women under the age of 50 should be aware of the risk of blood clots from the vaccine.

CDC’s Clinician Outreach and Communication Activity will hold a Zoom call Tuesday, April 27 at 2 p.m. ET to discuss the latest evidence on thrombosis with thrombocytopenia syndrome after the administration of the Johnson & Johnson vaccine. Access the live webinar here, a recording of which will be available several hours after the live event ends.
 

Related News Articles

Headline
The Food and Drug Administration today announced the expansion of its emergency use authorization for Pfizer’s COVID-19 vaccine to include adolescents ages 12…
Headline
Illinois health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence in…
Blog
The Centers for Medicare & Medicaid Services recently announced that Medicare will not continue to cover audio-only telehealth visits when the COVID-19…
Headline
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase…
Headline
The Centers for Disease Control’s independent advisory committee will meet May 12 for what’s expected to be a discussion of Pfizer’s request to authorize the…
Headline
In this AHA video for Mother’s Day, part of AHA’s #MyWhy social media campaign, a pregnant health care worker explains why she chose to get…